CFO of Myriad Genetics Inc (30-Year Financial, Insider Trades) Richard Bryan Riggsbee (insider trades) sold 25,000 shares of MYGN on 08/01/2019 at an average price of $41.5 a share. The total sale was $1 million.
Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs. Myriad Genetics Inc has a market cap of $3.45 billion; its shares were traded at around $47.08 with a P/E ratio of 162.42 and P/S ratio of 4.13. Myriad Genetics Inc had annual average EBITDA growth of 7.90% over the past ten years. GuruFocus has detected 4 severe warning signs with Myriad Genetics Inc. .
CFO Recent Trades:
- CFO Richard Bryan Riggsbee sold 25,000 shares of MYGN stock on 08/01/2019 at the average price of $41.5. The price of the stock has increased by 13.45% since.
Directors and Officers Recent Trades:
- Exec. VP International Ops Gary A. King sold 60,000 shares of MYGN stock on 08/01/2019 at the average price of $43.49. The price of the stock has increased by 8.25% since.
- President Crescendo BioScience Bernard Tobin sold 11,712 shares of MYGN stock on 08/01/2019 at the average price of $40. The price of the stock has increased by 17.7% since.
- President & C.E.O. Mark Christopher Capone sold 137,000 shares of MYGN stock on 08/01/2019 at the average price of $44. The price of the stock has increased by 7% since.
For the complete insider trading history of MYGN, click here
.
